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Abstract
Background: While melanocytic nevi have been associated with genetic factors and childhood sun exposure, several
observations also suggest a potential hormonal influence on nevi. To test the hypothesis that nevi are associated with
breast tumor risk, we explored the relationships between number of nevi and benign and malignant breast disease risk.
Methods and Findings: We prospectively analyzed data from E3N, a cohort of French women aged 40–65 y at inclusion in
1990. Number of nevi was collected at inclusion. Hazard ratios (HRs) for breast cancer and 95% confidence intervals (CIs)
were calculated using Cox proportional hazards regression models. Associations of number of nevi with personal history of
benign breast disease (BBD) and family history of breast cancer were estimated using logistic regression. Over the period 15
June 1990–15 June 2008, 5,956 incident breast cancer cases (including 5,245 invasive tumors) were ascertained among
89,902 women. In models adjusted for age, education, and known breast cancer risk factors, women with ‘‘very many’’ nevi
had a significantly higher breast cancer risk (HR=1.13, 95% CI=1.01–1.27 versus ‘‘none’’; ptrend=0.04), although significance
was lost after adjustment for personal history of BBD or family history of breast cancer. The 10-y absolute risk of invasive
breast cancer increased from 3,749 per 100,000 women without nevi to 4,124 (95% CI=3,674–4,649) per 100,000 women
with ‘‘very many’’ nevi. The association was restricted to premenopausal women (HR=1.40, ptrend=0.01), even after full
adjustment (HR=1.34, ptrend=0.03; phomogeneity=0.04), but did not differ according to breast cancer type or hormone
receptor status. In addition, we observed significantly positive dose–response relationships between number of nevi and
history of biopsy-confirmed BBD (n=5,169; ptrend,0.0001) and family history of breast cancer in first-degree relatives
(n=7,472; ptrend=0.0003). The main limitations of our study include self-report of number of nevi using a qualitative scale,
and self-reported history of biopsied BBD.
Conclusions: Our findings suggest associations between number of nevi and the risk of premenopausal breast cancer, BBD,
and family history of breast cancer. More research is warranted to elucidate these relationships and to understand their
underlying mechanisms.
Please see later in the article for the Editors’ Summary.
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Melanocytic nevi (hereafter referred to as nevi) are benign skin
tumors resulting from epidermal melanocyte proliferation. They
occur more frequently in fair- than in dark-skinned individuals and
can be either congenital or acquired later in life. Nevus acquisition
starts early in childhood and peaks during puberty, then declines
in adulthood, with progressive loss with age [1]. Twin studies have
consistently demonstrated genetic heritability of number of nevi
[2–4], with an estimated 40%–80% of the variance in nevus
counts being attributable to genetic effects [2,4]. Genome-wide
association studies have indeed reported several genes involved in
nevus count, including CDKN2A and MTAP, both located at the
9p21 locus, and PLA2G6, located at 22q13 [5,6]. Childhood sun
exposure is also likely to play an important role in nevus
acquisition, as suggested by studies of site distribution of nevi in
children, which have consistently shown higher nevus densities on
habitually sun-exposed body sites [7–10]. Number of sunburns
[8,11–13] and low latitude [12,14–18] have also been associated
with increased nevus prevalence. Because number of nevi peaks
during puberty [1] and nevi are reported to be darker and larger
during pregnancy [19,20], a hormonal influence on nevi may also
be speculated. Consistently, melanocytes, the pigment-producing
cells, have been shown to express estrogen and androgen receptors
[21]. However, the role of sex hormones in the occurrence of nevi
remains to be determined.
Number of nevi is the strongest known risk factor for cutaneous
melanoma [22], and an association has been suggested between
melanoma and breast cancer [23,24]. In addition, number of nevi
and melanoma risk have been associated with variants in the
CDKN2A gene [6], which plays a role in cell cycle regulation, while
CDKN2A inactivation has been shown to be common in breast
cancer [25]. Number of nevi has also been found to be associated
with several benign and malignant diseases, particularly hormone-
related conditions, including endometriosis [26], leiomyoma [27],
and thyroid diseases [28]. Whether these associations are
explained by common hormonal or genetic pathways has not yet
been clarified.
In order to investigate whether nevus count is associated with
breast tumor risk, we explored the relationships between number
of nevi and the risks of benign and malignant breast diseases and
family history of breast cancer, in the French E3N prospective
cohort.
Methods
Ethics Statement
The E3N cohort received ethical approval from the French
National Commission for Computed Data and Individual
Freedom (Commission Nationale de l’Informatique et des
Liberte ´s), and all participants in the study provided informed
consent.
The E3N Cohort
E3N is a prospective cohort study involving 98,995 women born
in 1925–1950, living in metropolitan France at inclusion and
insured by the Mutuelle Ge ´ne ´rale de l’E ´ducation Nationale, a
national health scheme primarily covering teachers. The cohort
has been described in detail elsewhere [29]. Briefly, women were
enrolled from February 1, 1989, through November 30, 1991,
after returning a baseline self-administered questionnaire on their
lifestyle and medical history. Follow-up questionnaires were sent
every 2–3 y thereafter.
Breast Cancer Assessment
All cohort questionnaires inquired about the occurrence of
cancer, including breast cancer, requesting contact details of the
participants’ physicians and permission to contact them. A small
number of breast cancer cases were further identified from
insurance files and death certificates. Pathology reports were
obtained for 93% of incident cases. We also considered cases for
which pathology reports had not been obtained, because the
proportion of false-positive self-reports was low in our study
population (,5%). Information on ascertained estrogen receptor
(ER) and progesterone receptor (PR) status was extracted from
pathology reports, and invasive breast cancer cases were classified
accordingly into four categories: ER+/PR+,E R +/PR2,E R 2/
PR+, and ER2/PR2. Women with unknown receptor status—
mostly with tumors diagnosed in the early years of follow-up, when
determining hormone receptor status was not compulsory
(n=1,415, 27% of the tumors)—were excluded from the analyses
stratified according to hormone receptor status.
Benign Breast Disease Ascertainment
The 1990 and 1992 questionnaires asked women to report if
they had ever had a personal history of benign breast disease
(BBD) (breast adenoma or fibroadenoma, fibrocystic breast
disease, or other) before inclusion in the cohort (prevalent BBD,
n=19,742). Women also reported whether a biopsy had been
performed for these diseases. This information was then collected
prospectively in subsequent questionnaires (incident BBD,
n=11,600). To avoid the potential selection bias of including
only late-diagnosed BBD, both prevalent and incident BBDs were
included in the analyses. When history of BBD was analyzed as a
potential confounder, both biopsied and non-biopsied BBDs were
included in order to maximize statistical power; however, we
performed a sensitivity analysis excluding non-biopsied BBDs and
verified the stability of the findings. When history of BBD was
analyzed as an outcome, only biopsy-confirmed BBDs were
considered in order to minimize misclassification.
Assessment of Family History of Breast Cancer
Family history of breast cancer was collected in the inclusion
questionnaire, where participants were asked to self-report
whether their first-degree relatives had ever had a history of
breast cancer.
Assessment of Exposure and Covariates
The inclusion questionnaire asked women to self-report their
number of moles, with four possible answers: none, a few, many,
or very many. The questionnaire also inquired about education
level, skin complexion, height and weight, and physical activity.
Data on age at menarche, parity, age at first full-term pregnancy,
and breastfeeding were collected in the inclusion (1990) and 1992
questionnaires. Data on use of oral contraceptives (OCs),
premenopausal progestogens, and menopausal hormone therapy
(MHT) were collected in 1992 and updated in each follow-up
questionnaire. Body mass index (BMI) was calculated as weight in
kilograms, reported at inclusion and updated at each follow-up
questionnaire, divided by height in meters squared. Menopausal
status, age at menopause, and history of recent mammographic
exam (in the period since the previous questionnaire) were
collected at inclusion and at each follow-up questionnaire. To
obtain average levels of residential sun exposure during childhood
and adulthood, we linked data on county of birth and county of
residence at inclusion to a database from the Joint Research
Nevi and Breast Diseases
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ultraviolet (UV) radiation dose in French counties [30]. Physical
activity, height, and UV dose in county of birth and of residence at
baseline were analyzed in tertiles. BMI was grouped using World
Health Organization cutoff points of 18.5 and 25 kg/m
2, further
dividing those with BMI 18.5–25 kg/m
2 into the categories 18.5–
22.5 and 22.5–25 kg/m
2, according to the median BMI in our
study population. Age at menarche, age at first full-term
pregnancy, and age at menopause were categorized according to
the median for these variables in the cohort. Women were
considered postmenopausal if they reported 12 consecutive
months of amenorrhea (unless due to hysterectomy), bilateral
oophorectomy, or use of MHT, or if they self-reported being
postmenopausal. Date of menopause was defined as the date of last
menstrual period (unless due to hysterectomy, and if the last
menstrual period occurred before MHT use), date of bilateral
oophorectomy, or, in decreasing order of priority, self-reported
date of menopause, date MHT use began, or date menopausal
symptoms began; if no information on date of menopause was
available, date of menopause was defined as the date correspond-
ing to age 47 y if menopause was known to be artificial, or age
51 y otherwise, i.e., the median ages for artificial and natural
menopause in the cohort, respectively.
Statistical Analyses
Statistical analyses were performed using SAS software (version
9.3, SAS Institute). Hazard ratios (HRs) for breast cancer and 95%
confidence intervals (CIs) were estimated using Cox proportional
hazards regression models with age as the timescale. We also
calculated absolute risks of breast cancer associated with the
number of nevi. The association between number of nevi and
breast cancer risk was assessed using different adjustment models.
We first used age-adjusted models stratified by birth cohort in 5-y
categories (Model 1) and then built a model including as covariates
only those factors whose inclusion resulted in a 10% change of the
HR for number of nevi. Besides age and birth cohort, this model
included education (,12, 12–14, or $15 y), use of premenopausal
progestogens (ever/never), menopausal status (pre- or postmeno-
pausal), age at menopause in postmenopausal women (,51 or
$51 y), and use of MHT in postmenopausal women (ever/never)
(Model 2). Because further adjustment for personal history of BBD
or family history of breast cancer resulted in the largest changes in
HRs for breast cancer, we evaluated their effect separately by
creating two models, Model 2 further adjusted for personal history
of BBD (Model 3) and Model 3 additionally adjusted for family
history of breast cancer (Model 4). Finally, a fully adjusted model
included all the preceding covariates along with the remaining
potential confounders, including BMI, height, physical activity,
age at menarche, parity, age at first full-term pregnancy,
breastfeeding, use of OCs, personal history of mammographic
exam, and UV dose in county of birth and of residence at cohort
inclusion (Model 5). All models were generated both for in situ and
invasive breast cancer cases combined, and for in situ and invasive
cases separately, and homogeneity tests were used to compare
estimates between in situ and invasive cases. We performed tests
for linear trend across categories of number of nevi by assigning a
numerical value to each category. Effect modification was
evaluated using interaction tests. In addition, we stratified the
analyses according to menopausal status, and we performed
stratified analyses according to hormone receptor status or tumor
histological type in invasive cases using competing-risk models
[16]. We performed homogeneity tests to compare risk estimates
across strata.
We additionally used a case–control design to explore the
relationships between number of nevi and (1) personal history of
BBD and (2) family history of breast cancer in first-degree
relatives. For this analysis, unconditional logistic regression models
were used to estimate odds ratios (ORs) and 95% CIs. For history
of BBD, potential confounders were included only if their inclusion
resulted in at least a 10% change in the OR. Final models included
age at cohort inclusion, age at last returned questionnaire,
education, premenopausal progestogens, menopausal status, age
at menopause, use of MHT in postmenopausal women, and family
history of breast cancer. For family history of breast cancer,
models included education and age at cohort inclusion.
For all analyses, missing values in covariates were imputed to
the modal category if values were missing in ,5% of observations,
otherwise a ‘‘missing’’ category was created for the covariate.
Regarding our exposure of interest, women with no information
on number of nevi (n=2,211; 2.2% of the total cohort) were more
likely to be older, to have a late menarche, to be younger at their
first full-term pregnancy, and to be nulliparous, but were less likely
to have a high education level or a high physical activity level at
baseline; to be overweight or obese; to be tall; to have ever used
OCs, premenopausal progestogens, or MHT; to have ever
breastfed; to have ever had a history of BBD, a mammographic
exam, or a family history of breast cancer; or to have a high UV
dose in their county of residence at baseline compared to those
with available data on this factor (Table S1). However, given the
low rate of missing values in this variable (2.2%), we speculate that
exclusion of missing data would have little impact on the findings;
we thus excluded participants lacking information on number of
nevi from all analyses.
Population for Analysis
From the original study population, we excluded women with
missing data on number of nevi (n=2,211), with a cancer history
before inclusion (n=5,024), lost to follow-up after they replied to
the inclusion questionnaire (n=1,931), or with primary amen-
orrhea (n=27). Our final sample for analysis consisted of 89,802
women. Woman-years were computed from the date the first
questionnaire was returned to the date of diagnosis of breast
cancer or any other cancer, date of last questionnaire returned,
or date of end of follow-up (June 25, 2008), whichever occurred
first.
For the analyses exploring number of nevi in relation to history
of BBD, we further excluded women with non-biopsied BBD
(n=26,173). For analyses exploring family history of breast cancer,
we excluded from the original study population women with
missing data on number of nevi (n=2,211) and those with missing
data on family history of breast cancer (n=728). The final study
populations for these analyses included 63,629 women for history
of BBD and 96,056 women for family history of breast cancer.
Results
Over 1,385,970 woman-years and a median follow-up of 17.9 y,
a total of 5,956 incident breast cancer cases (including 5,245
invasive and 711 in situ cases) were ascertained among the 89,902
included women. Table 1 describes the baseline characteristics of
the participants according to number of nevi. Women with a high
number of nevi were more likely to be from more recent birth
cohorts; to have a high education level; to be tall ($164 cm); to
have an early menarche (,13 y of age); to have ever used OCs,
premenopausal progestogens, or MHT; to have ever breastfed; to
be premenopausal; and to have a history of BBD. In contrast, they
were less likely to be physically active, to be overweight or obese,
Nevi and Breast Diseases
PLOS Medicine | www.plosmedicine.org 3 June 2014 | Volume 11 | Issue 6 | e1001660Table 1. Baseline characteristics of the study population.
Characteristic Number of Nevi p-Value
a
None (n=9,044) A Few (n=33,187) Many (n=37,911) Very Many (n=9,660)
Year of birth
,1930 1,266 (14.0) 2,913 (8.8) 2,143 (5.7) 382 (4.0) ,0.0001
1930–1934 1,684 (18.6) 4,790 (14.4) 4,028 (10.6) 785 (8.1)
1935–1939 2,053 (22.7) 6,738 (20.3) 6,654 (17.5) 1,332 (13.8)
1940–1945 1,911 (21.1) 7,891 (23.8) 9,538 (25.2) 2,389 (24.7)
$1950 2,130 (23.6) 10,855 (32.7) 15,548 (41.0) 4,772 (49.4)
Education
,12 y 1,724 (19.1) 1,724 (14.9) 4,519 (11.9) 804 (8.3) ,0.0001
12–14 y 4,766 (52.7) 4,766 (52.6) 19,466 (51.4) 4,792 (49.6)
$15 y 2,554 (28.2) 2,554 (32.5) 13,926 (36.7) 4,064 (42.1)
Physical activity at inclusion
(MET-h/wk)
,13.8 2,274 (25.1) 7,820 (23.6) 8,814 (23.3) 2,328 (24.1) ,0.0001
13.8–25.0 3,147 (34.8) 12,193 (36.7) 14,448 (38.1) 3,831 (39.7)
$25.0 3,623 (40.1) 13,174 (39.7) 14,649 (38.6) 3,501 (36.2)
BMI (kg/m
2)
,18.5 343 (3.8) 1,336 (4.0) 1,740 (4.6) 496 (5.1) ,0.0001
18.5–22.4 4,378 (48.4) 17,674 (53.3) 20,724 (54.7) 5,446 (56.4)
22.5–24 2,448 (27.1) 8,332 (25.1) 9,252 (24.4) 2,254 (23.3)
$25 1,875 (20.7) 5,845 (17.6) 6,195 (16.3) 1,464 (15.2)
Height (cm)
,160 3,299 (36.5) 11,285 (34.0) 11,968 (31.6) 2,758 (28.5) ,0.0001
160–163 2,728 (30.2) 10,068 (30.3) 11,383 (30.0) 2,933 (30.4)
$164 3,017 (33.3) 11,834 (35.7) 14,560 (38.4) 3,969 (41.1)
Age at menarche
,13 y 3,876 (42.9) 14,916 (45.0) 17,377 (45.8) 4,485 (46.4) ,0.0001
$13 y 5,168 (57.1) 18,271 (55.0) 20,534 (54.2) 5,175 (53.6)
OC use
Never 4,515 (49.9) 13,979 (42.1) 13,873 (36.6) 3,052 (31.6) ,0.0001
Ever 4,529 (50.1) 19,208 (57.9) 24,038 (63.4) 6,608 (68.4)
Age at first full-term pregnancy
(in parous women)
,30 y 7,025 (89.1) 26,091 (88.7) 29,431 (87.5) 7,298 (85.7) ,0.0001
$30 y 857 (10.9) 3,336 (11.3) 4,221 (12.5) 1,221 (14.3)
Parity
Nulliparous 1,162 (12.9) 3,762 (11.3) 4,259 (11.2) 1,141 (11.8) ,0.0001
1–2 full-term pregnancies 5,020 (55.5) 19,515 (58.8) 22,806 (60.2) 5,923 (61.3)
$3 full-term pregnancies 2,862 (31.6) 9,910 (29.9) 10,846 (28.6) 2,596 (26.9)
Breastfeeding
b
Never 3,462 (38.3) 12,353 (37.2) 13,540 (35.7) 3,411 (35.3) ,0.0001
Ever 4,533 (50.1) 17,245 (52.0) 20,324 (53.6) 5,316 (55.0)
Unknown 1,049 (11.6) 3,589 (10.8) 4,047 (10.7) 933 (9.7)
Use of premenopausal
progestogens
Never 6,436 (71.2) 21,239 (64.0) 22,211 (58.6) 5,143 (53.2) ,0.0001
Ever 2,608 (28.8) 11,948 (36.0) 15,700 (41.4) 4,517 (46.8)
Menopausal status
Premenopausal 4,104 (45.4) 18,567 (56.0) 24,600 (64.9) 6,926 (71.7) ,0.0001
Postmenopausal 4,940 (54.6) 14,620 (44.0) 13,311 (35.1) 2,734 (28.3)
Nevi and Breast Diseases
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their first live birth before the age of 30 y.
In age-adjusted models, women in the highest category of
number of nevi had a significantly higher breast cancer risk
(HR=1.17, 95% CI=1.05–1.31; ptrend=0.006) compared to
those in the lowest (Table 2). The association remained in Model
2; however, associations were reduced and were no longer
statistically significant after additional adjustment for history of
BBD (Model 3, HR=1.10, 95% CI=0.98–1.23) and family
history of breast cancer (Model 4, HR=1.09, 95% CI=0.98–
1.22). The association was observed for both in situ and invasive
tumors, with no evidence of heterogeneity across these groups
(phomogeneity=0.27 in Model 2); however, the HR for number of
nevi in invasive cases was statistically significant in the model
adjusted only for age (Model 1). The 10-y absolute risk of invasive
breast cancer increased from 3,749 per 100,000 women without
nevi to 4,124 (95% CI=3,674–4,649) per 100,000 women with
‘‘very many’’ nevi.
Although ‘‘none’’ was the obvious reference category to explore
number of nevi, it was the smallest category in our cohort, and it
could be argued that this could inflate error estimates. However,
since the ‘‘none’’ group was not small per se—it included over
9,000 participants—and since our findings were not substantially
modified when testing different reference groups for this variable
(‘‘none/a few’’: Table S2; ‘‘a few’’: Table S3), we kept ‘‘none’’ as
the reference category for number of nevi in all subsequent
analyses.
No significant interactions were found between number of nevi
and history of BBD (pinteraction=0.27) or family history of breast
cancer (pinteraction=0.97) for the risk of breast cancer. We also
detected no significant interaction of number of nevi with skin
color (pinteraction=0.73), physical activity at inclusion (pinterac-
tion=0.17), UV dose in county of birth (pinteraction=0.07), or UV
dose in county of residence at inclusion (pinteraction=0.06). Since
the p-values for the last two factors were close to statistical
significance, we conducted stratified analyses according to the
median of UV dose in county of birth (Table S4) and according to
the median of UV dose in county of residence at baseline (Table
S5); however, we observed no significant heterogeneity across
these strata.
When stratifying the analysis according to menopausal status,
we detected significant heterogeneity across strata (phomogene-
ity=0.04). The association was restricted to premenopausal
women, in whom the relation remained even in the multivariable
model (HR=1.34, 95% CI=1.00–1.81 for ‘‘very many’’ versus
‘‘none’’; ptrend=0.03) (Table 3), corresponding to a 10-y absolute
Table 1. Cont.
Characteristic Number of Nevi p-Value
a
None (n=9,044) A Few (n=33,187) Many (n=37,911) Very Many (n=9,660)
Age at menopause
c
,51 y 2,907 (58.9) 8,707 (59.6) 8,172 (61.4) 1,732 (63.4) ,0.0001
$51 y 2,033 (41.2) 5,913 (40.4) 5,139 (38.6) 1,002 (36.7)
MHT use
c
Never 2,957 (59.9) 8,157 (55.8) 6,996 (52.6) 1,334 (48.8) ,0.0001
Ever 1,983 (40.1) 6,463 (44.2) 6,315 (47.4) 1,400 (51.2)
History of BBD
Never 7,410 (81.9) 26,240 (79.1) 29,309 (77.3) 7,101 (73.5) ,0.0001
Ever 1,634 (18.1) 6,947 (20.9) 8,602 (22.7) 2,559 (26.5)
History of mammographic exam
Never 2,746 (30.4) 9,662 (29.1) 10,824 (28.6) 2,733 (28.3) 0.003
Ever 6,298 (69.6) 23,525 (70.9) 27,087 (71.5) 6,927 (71.7)
Family history of breast cancer
No 8,414 (93.0) 30,642 (92.3) 35,071 (92.5) 8,891 (92.0) 0.05
Yes 630 (7.0) 2,545 (7.7) 2,840 (7.5) 769 (8.0)
UV dose in county of birth
b
,1.40 2,727 (30.2) 9,567 (28.8) 11,188 (29.5) 2,777 (28.8) ,0.0001
1.40–1.61 2,634 (29.1) 9,972 (30.1) 11,868 (31.3) 3,006 (31.1)
$1.61 2,994 (33.1) 10,982 (33.1) 11,699 (30.9) 2,938 (30.4)
Missing 689 (7.6) 2,666 (8.0) 3,156 (8.3) 939 (9.7)
UV dose in county of residence
at inclusion
,1.40 2,680 (29.6) 9,688 (29.2) 11,313 (29.8) 2,842 (29.4) ,0.0001
1.40–1.63 3,127 (34.6) 11,779 (35.5) 13,834 (36.5) 3,598 (37.3)
$1.63 3,237 (35.8) 11,720 (35.3) 12,764 (33.7) 3,220 (33.3)
aFrom chi-square tests.
bTests were performed excluding participants in the unknown/missing category.
cAmong postmenopausal women.
MET, metabolic equivalent of task.
doi:10.1371/journal.pmed.1001660.t001
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PLOS Medicine | www.plosmedicine.org 7 June 2014 | Volume 11 | Issue 6 | e1001660risk of invasive breast cancer of 2,515 per 100,000 women with no
nevi versus 3,370 (95% CI=2,515–4,552) per 100,000 women
with ‘‘very many’’ nevi. Subgroup analyses according to histolog-
ical type of breast cancer (ductal carcinoma, lobular carcinoma, or
other) (Table 4) or ER/PR status (Table 5) yielded no significant
heterogeneity.
Associations between number of nevi and BBD and family
history of breast cancer are reported in Tables 6 and 7. We
observed positive dose–response relationships between number of
nevi and a personal history of biopsy-confirmed BBD (ORs of
1.14, 1.15, and 1.26 across increasing categories of number of
nevi; ptrend,0.0001) and family history of breast cancer in first-
degree relatives (ORs of 1.14, 1.15, and 1.25 across increasing
categories of number of nevi; ptrend=0.0003).
Discussion
In the present study, we found a modest association between
number of nevi and overall breast cancer risk, which was restricted
to premenopausal women. In these women, the highest versus
lowest category of number of nevi was associated with a HR of
1.34 for breast cancer (10-y absolute risk of invasive breast cancer
of 2,515 per 100,000 women with no nevi versus 3,370 [95%
CI=2,515–4,552] per 100,000 women with ‘‘very many’’ nevi). A
high number of nevi was also associated with the risk of biopsy-
confirmed BBD and with family history of breast cancer in first-
degree relatives. While adjustment for personal history of BBD
and family history of breast cancer reduced the association
between number of nevi and overall breast cancer risk, it did not
substantially modify the association with premenopausal breast
cancer risk.
While a causal relationship between number of nevi and breast
disease risk seems unlikely, our observed associations between
number of nevi and risk of premenopausal breast cancer, history of
BBD, and family history of breast cancer may suggest at least two
potential mechanisms.
One potential mechanism is that these relations could reflect a
common hormonal influence on nevi and breast diseases. The fact
that significant associations were restricted to premenopausal
breast cancer and that number of nevi was associated with both
BBD and breast cancer risk are consistent with this hypothesis,
although we failed to find a stronger association with ER+ than
with ER2 tumors, possibly because of a lack of power in subgroup
analyses. Consistent with this hypothesis, melanocytes are known
to express estrogen and androgen receptors [21], melanogenesis is
known to be influenced by endogenous sex hormones [21,31], and
a transient increase in nevi darkness and diameter has been
observed during pregnancy [19,20,32]. Nonetheless, if this hypoth-
esis were true, then an increase in nevus number should also be
observed during pregnancy or MHT use, when endogenous female
hormone levels are substantially increased. However, no previous
study to our knowledge has made this observation to date.
A second potential mechanism is that nevi and breast diseases
could share genetic factors, which is consistent with our observed
association between number of nevi and family history of breast
cancer. Interestingly, several studies have reported associations
between melanoma and breast cancer, finding either a higher risk
of breast cancer following melanoma diagnosis [33–37] or the
opposite [23,24,34,38–48], and a higher breast cancer risk was
reported in melanoma-prone families carrying CDKN2A mutations
[49]. Among genetic factors that could account for a common
heritability between nevus count and breast cancer, one potential
candidate is CDKN2A, a tumor suppressor gene encoding cyclin-
dependent kinase inhibitors known to be frequently mutated or
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PLOS Medicine | www.plosmedicine.org 8 June 2014 | Volume 11 | Issue 6 | e1001660suppressed in a number of cancers. This gene has been identified
as a high penetrance susceptibility gene for melanoma, with
germline mutations occurring in 20%–40% of families with three
or more melanoma cases [50], and it has also been associated with
nevus count in recent genome-wide association studies [6,51]. In
addition, a SNP located in a block encompassing CDKN2A and
CDKN2B at 9p21, rs1011970, was reported to be associated with
breast cancer in a recent genome-wide scan [52]. The association
was later confirmed in a pooled study, in which similar associations
were reported in ER+ and ER2 tumors [53].
CDKN2A codes for two proteins, p14 and p16 [54]. By
competing with cyclin D1 for CDK4/6 binding, p16 inhibits the
expression and transcription of cyclin D1, one of the main
mediators of the proliferative action of estrogens [55]. Silencing of
p16 protein expression through epigenetic mechanisms, or
because of a germline mutation, has been suspected to play a
crucial role in the progression of intraductal proliferative lesions
[56] and has been associated with breast cancer risk, particularly
in young women [57]. Moreover, estradiol-induced cell prolifer-
ation in the case of p16-enhanced cyclin D1 expression may be
amplified in a highly estrogenic environment. This may be
consistent with our finding that the association between number of
nevi and breast cancer risk is restricted to premenopausal women.
However, because it is unclear whether the associations we
found reflect common hormonal, genetic, or environmental
pathways, more research is warranted to understand their
underlying biological mechanisms.
Strengths of our study include the large sample size and
prospective design of the E3N cohort; we also had detailed data on
breast cancer cases, personal history of BBD, and family history of
breast cancer.
The main limitation regarded self-report of nevi number, and
use of a qualitative scale instead of counts. Repeatability studies of
number of nevi indeed show a moderate reliability [58–60].
However, in this cohort of mostly educated women, self-reported
features have demonstrated high reproducibility in several
validation studies [61–63]. In addition, number of nevi showed a
strong dose–response relationship with the risk of cutaneous
melanoma in our cohort [64], which suggests satisfactory validity
for this variable. Also, misclassification, if any, would be non-
differential and independent from the studied outcomes, and
would thus likely result in underestimating existing relationships.
Another limitation is that race information was not available in
our cohort, as this type of question is not acceptable to French
ethical committees. However, while E3N women did report their
skin color, we detected no significant interaction in our findings
according to this factor. Further, while the large sample size of our
cohort makes it possible to detect small associations, our findings
regarding breast cancer risk were of modest effect size and
sensitive to adjustment, particularly for history of BBD and family
history of breast cancer, for which we found an independent
association with number of nevi. Also, given the number of
interaction tests that we performed, some of our findings could be
attributable to chance and should therefore be interpreted with
caution. However, while a multiple testing issue can arise when a
high number of hypothesis-free tests are performed [65], the
significant interaction between menopausal status and nevi
number with regard to breast cancer risk is based on known
heterogeneity of breast cancer risk factors according to this
characteristic.
Another limitation was that history of BBD was self-reported
and could not always be confirmed through biopsy reports, which
may have introduced some degree of misclassification. However,
when we studied BBD as a potential confounder, our results were
unchanged whether analyses included all BBDs or biopsied BBDs
only, and when we studied history of BBD as an outcome,
restricting the analyses to biopsy-confirmed BBD likely reduced
this bias.
Another potential bias could arise from a complex relationship
between UV exposure, number of nevi, and vitamin D levels.
Table 6. Odds ratios and 95% confidence intervals for number of nevi in relation to history of benign breast disease, E3N cohort.
Number of Nevi n History of BBD Crude OR (95% CI) Multivariable OR
a (95% CI)
None 6,852 427 1.00 (Reference) 1.00 (Reference)
A few 23,930 1,813 1.23 (1.11–1.38) 1.14 (1.01–1.29)
Many 26,417 2,251 1.40 (1.26–1.56) 1.15 (1.02–1.30)
Very many 6,430 678 1.77 (1.56–2.01) 1.26 (1.08–1.47)
ptrend ,0.0001 0.008
aAdjusted for age at cohort inclusion, age at last returned questionnaire, education, menopausal status, age at menopause (in postmenopausal women), use of MHT (in
postmenopausal women), use of premenopausal progestogens, and family history of breast cancer.
doi:10.1371/journal.pmed.1001660.t006
Table 7. Odds ratios and 95% confidence intervals for number of nevi in relation to family history of breast cancer, E3N cohort.
Number of Nevi n Family History of Breast Cancer Crude OR (95% CI) Multivariable OR
a (95% CI)
None 9,657 693 1.00 (Reference) 1.00 (Reference)
A few 35,503 2,791 1.10 (1.01–1.20) 1.14 (1.05–1.24)
Many 40,475 3,130 1.08 (1.00–1.18) 1.15 (1.06–1.25)
Very many 10,421 858 1.16 (1.05–1.29) 1.25 (1.13–1.39)
ptrend 0.05 0.0003
aAdjusted for education and age at inclusion.
doi:10.1371/journal.pmed.1001660.t007
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PLOS Medicine | www.plosmedicine.org 9 June 2014 | Volume 11 | Issue 6 | e1001660Indeed, exposure to UVB rays results in higher vitamin D
synthesis, and normal versus insufficient or deficient vitamin D
levels in adulthood have been associated with a reduced breast
cancer risk [66]. Because number of nevi increases with sun
exposure, UV exposure may act as a confounder in the association
between number of nevi and breast cancer risk. Although our
models were adjusted for residential UV dose, level of recreational
sun exposure was not available, and we thus cannot rule out
residual confounding, which would most likely result in reducing
the strength of an association between number of nevi and breast
cancer risk. Thus, it is unlikely that the observed associations
between premenopausal breast cancer risk result from confound-
ing, but regarding the absence of an association with postmeno-
pausal breast cancer, we cannot rule out some residual negative
confounding.
In conclusion, these data from a large prospective cohort study
suggest associations between number of nevi and risk of
premenopausal breast cancer, history of BBD, and family history
of breast cancer. Because associations were modest and the results
for breast cancer were sensitive to adjustment, we mostly consider
our findings in terms of enhancement of our knowledge of
pathophysiological mechanisms. More research is warranted
before these findings could possibly be used in diagnosis or
screening scores for breast cancer. If confirmed, these findings may
suggest that nevi could be associated with other markers of breast
cancer risk, such as mammographic density, which should warrant
a specific study.
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Background. In 2012, nearly 1.7 million women worldwide
discovered they had breast cancer, and about half a million
women died from the disease. Breast cancer begins when
cells in the breast acquire genetic changes that allow them
to divide uncontrollably and to move around the body
(metastasize). Uncontrolled cell division leads to the forma-
tion of a lump that can be detected by mammography (a
breast X-ray) or by manual breast examination. Breast cancer
is treated by surgical removal of the lump, or, if the cancer
has started to spread, by removal of the whole breast
(mastectomy). Surgery is usually followed by radiotherapy or
chemotherapy to kill any remaining cancer cells. Because the
female sex hormones estrogen and progesterone stimulate
the growth of some tumors, drugs that block hormone
receptors are also used to treat receptor-positive breast
cancer. Nowadays, the prognosis (outlook) for women with
breast cancer is good, and in developed countries, nearly
90% of affected women are still alive five years after
diagnosis.
Why Was This Study Done? Several hormone-related
factors affect a woman’s chances of developing breast
cancer. For example, women who have no children or who
have them late in life have a higher breast cancer risk than
women who have several children when they are young
because pregnancy alters sex hormone levels. Interestingly,
the development of moles (nevi)—dark skin blemishes that
are risk factors for the development of melanoma, a type of
skin cancer—may also be affected by estrogen and
progesterone. Thus, the number of nevi might be a marker
of blood hormone levels and might predict breast cancer
risk. In this prospective cohort study, the researchers test this
hypothesis by investigating the association between how
many moles a woman has and her breast cancer risk. A
prospective cohort study enrolls a group (cohort) of people,
determines their baseline characteristics, and follows them
over time to see which characteristics are associated with the
development of specific diseases.
What Did the Researchers Do and Find? In 1990, the
E3N prospective cohort study enrolled nearly 100,000 French
women (mainly school teachers) aged 40–65 years to
investigate cancer risk factors. The women completed a
baseline questionnaire about their lifestyle and medical
history, and regular follow-up questionnaires that asked
about cancer occurrence. In the initial questionnaire, the
women indicated whether they had no, a few, many, or very
many moles. Between 1990 and 2008, nearly 6,000 women in
the cohort developed breast cancer. Using statistical
methods to calculate hazard ratios (an ‘‘HR’’ compares how
often a particular event happens in two groups with
different characteristics; an HR greater than one indicates
that a specific characteristic is associated with an increased
risk of the event), the researchers report that women with
‘‘very many’’ nevi had a significantly higher breast cancer risk
(a higher risk that was unlikely to have occurred by chance)
than women with no nevi. Specifically, the age-adjusted HR
for breast cancer among women with ‘‘very many’’ nevi
compared to women with no nevi was 1.17. After adjustment
for a personal history of benign (noncancerous) breast
disease and a family history of breast cancer (two established
risk factors for breast cancer), the association between nevi
and breast cancer risk among the whole cohort became
nonsignificant. Notably, however, the association among
only premenopausal women remained significant after full
adjustment (HR=1.34), which corresponded to an increase in
ten-year absolute risk of invasive breast cancer from 2,515
per 100,000 women with no nevi to 3,370 per 100,000
women with ‘‘very many’’ nevi.
What Do These Findings Mean? These findings suggest
that among premenopausal women there is a modest
association between nevi number and breast cancer risk.
This noncausal relationship may indicate that nevi and breast
diseases are affected in similar ways by hormones or share
common genetic factors, but the accuracy of these findings
may be limited by aspects of the study design. For example,
self-report of nevi numbers using a qualitative scale may
have introduced some inaccuracies into the estimates of the
association between nevi number and breast cancer risk.
Most importantly, these findings are insufficient to support
the use of nevi counts in breast cancer screening or
diagnosis. Rather, together with the findings reported by
Zhang et al. in an independent PLOS Medicine Research
Article, they suggest that further studies into the biological
mechanisms underlying the relationship between nevi and
breast cancer and the association itself should be undertak-
en.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001660.
N This study is further discussed in a PLOS Medicine
Perspective by Fuhrman and Cardenas
N An independent PLOS Medicine Research Article by Zhang
et al. also investigates the relationship between nevi
number and breast cancer risk
N The US National Cancer Institute provides comprehensive
information about cancer (in English and Spanish),
including detailed information for patients and profession-
als about breast cancer; it also has a fact sheet on moles
N Cancer Research UK, a not-for profit organization, provides
information about cancer, including detailed information
on breast cancer
N The UK National Health Service Choices website has
information and personal stories about breast cancer; the
not-for profit organization Healthtalkonline also provides
personal stories about dealing with breast cancer
N More information about the E3N prospective cohort study
is available; detailed information is available in French
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